# A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

> **NCT04302103** · PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 29 (actual)

## Conditions studied

- Systemic Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** RC18 160mg
- **BIOLOGICAL:** RC18 240 mg

## Key facts

- **NCT ID:** NCT04302103
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-02-11
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04302103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04302103, "A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04302103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*